ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Alimera Sciences, Inc." (ALIM) Report Updated: Jul 28, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Alimera Sciences, Inc." (ALIM)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Pharmaceuticals
Competitors: SHPG, ANIP, LCI, AKRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Alimera Sciences, Inc."© quotemedia

Company Profile

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that takes advantage of the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide. The company is also conducting three Phase III clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it is developing ILUVIEN Applicator, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Recent News: "Alimera Sciences, Inc."